| AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ... New England Journal of Medicine 371 (11), 1028-1038, 2014 | 2937 | 2014 |
| Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial R Phillips, WY Shi, M Deek, N Radwan, SJ Lim, ES Antonarakis, SP Rowe, ... JAMA oncology 6 (5), 650-659, 2020 | 947 | 2020 |
| A history of prostate cancer treatment SR Denmeade, JT Isaacs Nature Reviews Cancer 2 (5), 389-396, 2002 | 794 | 2002 |
| Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ... JAMA oncology 1 (5), 582-591, 2015 | 702 | 2015 |
| Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer SR Denmeade, XS Lin, JT Isaacs The prostate 28 (4), 251-265, 1996 | 598 | 1996 |
| Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer DC Danila, MJ Morris, JS De Bono, CJ Ryan, SR Denmeade, MR Smith, ... Journal of Clinical Oncology 28 (9), 1496-1501, 2010 | 541 | 2010 |
| Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with … ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, Y Zhu, JL Silberstein, ... Journal of Clinical Oncology 35 (19), 2149-2156, 2017 | 469 | 2017 |
| Germline mutations in ATM and BRCA1/2 distinguish risk for lethal and indolent prostate cancer and are associated with early age at death R Na, SL Zheng, M Han, H Yu, D Jiang, S Shah, CM Ewing, L Zhang, ... European urology 71 (5), 740-747, 2017 | 389 | 2017 |
| Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer SR Denmeade, CM Jakobsen, S Janssen, SR Khan, ES Garrett, H Lilja, ... Journal of the National Cancer Institute 95 (13), 990-1000, 2003 | 353 | 2003 |
| The SERCA pump as a therapeutic target: making a “smart bomb” for prostate cancer SR Denmeade, JT Isaacs Cancer biology & therapy 4 (1), 21-29, 2005 | 288 | 2005 |
| Rationale behind targeting fibroblast activation protein–expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy WN Brennen, JT Isaacs, SR Denmeade Molecular cancer therapeutics 11 (2), 257-266, 2012 | 281 | 2012 |
| Androgens regulate vascular endothelial growth factor content in normal and malignant prostatic tissue. IB Joseph, JB Nelson, SR Denmeade, JT Isaacs Clinical cancer research: an official journal of the American Association …, 1997 | 274 | 1997 |
| Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen SR Denmeade, W Lou, J Lövgren, J Malm, H Lilja, JT Isaacs Cancer research 57 (21), 4924-4930, 1997 | 271 | 1997 |
| Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study MT Schweizer, ES Antonarakis, H Wang, AS Ajiboye, A Spitz, H Cao, ... Science translational medicine 7 (269), 269ra2-269ra2, 2015 | 269 | 2015 |
| Engineering a prostate-specific membrane antigen–activated tumor endothelial cell prodrug for cancer therapy SR Denmeade, AM Mhaka, DM Rosen, WN Brennen, S Dalrymple, I Dach, ... Science translational medicine 4 (140), 140ra86-140ra86, 2012 | 251 | 2012 |
| Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise TEG Krueger, DLJ Thorek, SR Denmeade, JT Isaacs, WN Brennen Stem cells translational medicine 7 (9), 651-663, 2018 | 249 | 2018 |
| Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen SR Denmeade, A Nagy, J Gao, H Lilja, AV Schally, JT Isaacs Cancer research 58 (12), 2537-2540, 1998 | 218 | 1998 |
| Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug WN Brennen, DM Rosen, H Wang, JT Isaacs, SR Denmeade Journal of the National Cancer Institute 104 (17), 1320-1334, 2012 | 205 | 2012 |
| Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study BA Teply, H Wang, B Luber, R Sullivan, I Rifkind, A Bruns, A Spitz, ... The Lancet Oncology 19 (1), 76-86, 2018 | 189 | 2018 |
| Knockin of mutant PIK3CA activates multiple oncogenic pathways JP Gustin, B Karakas, MB Weiss, AM Abukhdeir, J Lauring, JP Garay, ... Proceedings of the National Academy of Sciences 106 (8), 2835-2840, 2009 | 186 | 2009 |
